Navigation Links
Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
Date:6/5/2008

-Results Will be Presented at the American Society for Mass Spectrometry

56th ASMS Conference in Denver, June 2-5, 2008-

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced that it has developed a novel analytical 2-dimensional liquid chromatography mass spectrometry-based (LC/LC-MS/MS) multiplexing platform that allows for the rapid, specific, sensitive automated quantification of the active pharmaceutical compounds of MF101, the company's most advanced drug candidate. The novel quantification has been initially developed for, MF101, which is botanically derived, and has shown positive Phase 2 results for the treatment of hot flashes associated with menopause. The assay was validated in multiple matrices ranging from MF101 extracts for production quality control to plasma in pharmacokinetic and safety trials.

"The development of botanical drugs is far more challenging than a single molecule drug, since these are complex mixtures containing a number of bioactive compounds," said the lead author, Dr. Yan Ling Zhang, Bionovo's Director, Analytical Chemistry. "Our assay is capable of sensitively and specifically quantifying all active MF101 compounds in one short analytical run, and allows us to prove the exquisite precision and consistency of our manufacturing process. This is a tremendous advantage over conventional assays that usually only measure single compounds."

"The availability of this robust high-throughput assay is a key to the fast and successful development of MF101," said Dr. Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "Having the tool to quantify multiple actives solves important questions for manufacturing controls, dose assessment and safety measures. This analytical platform technology is critical to move MF101 quickly through the regulatory process."

About MF101

MF101 is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to those products currently on the market, which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with estrogen receptor alpha (ER-a) activation and that estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile to hormone therapy. The drug candidate has been evaluated by an independent Data and Safety Monitoring Board and has passed through a standard two-round examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer

-- markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):